Researchers at the University of Massachusetts Amherst have developed an artificial intelligence model called MycoPermeNet to accelerate the discovery of tuberculosis drugs. By combining this AI with a high-throughput screening technique known as PAC-MAN, the team can predict which chemical compounds can penetrate the bacterium’s unique mycomembrane, potentially speeding up the search for effective treatments for the deadly infection.
Why is the tuberculosis bacterium so resilient to antibiotics?
Tuberculosis, caused by the bacterium Mycobacterium tuberculosis (Mtb), remains the world’s deadliest single-agent caused infection. According to the World Health Organization, the disease was responsible for 1.23 million deaths in 2024.
The bacterium’s resilience stems from a unique outer cell membrane known as the mycomembrane. This biological barrier is exceptionally difficult for drugs and antibiotics to penetrate. Sloan Siegrist, an associate professor of microbiology at UMass Amherst, stated that the Mtb outer membrane is unlike any other biological barrier out there.
Because this membrane protects the cell from antimicrobial chemical compounds, finding effective treatments requires identifying specific “chinks” in the mycomembrane that allow drugs to pass through.
The mycomembrane is so effective at blocking substances that it protects Mtb from both the body’s immune system and antibiotics.
How does the PAC-MAN technique improve screening efficiency?
Historically, researchers had to test chemical compounds one at a time to determine if they could enter Mtb cells. This process is slow and limited by the vast number of possible chemical combinations.
In 2023, Siegrist and Marcos Pires, a professor of chemistry at the University of Virginia, introduced a technique called Peptidoglycan Accessibility Click-Mediated AssessmeNt (PAC-MAN). This method allows researchers to test many compounds in parallel, significantly increasing the speed of the screening process compared to traditional one-by-one testing.
What makes MycoPermeNet different from traditional drug testing?
While PAC-MAN increased testing speed, researchers sought a way to use data from known chemicals to predict how unknown chemicals would behave. This led to the development of MycoPermeNet, the Mycobacterial Permeability neural Network.
Developed by Anna Green, an assistant professor in UMass Amherst’s Manning College of Information and Computer Sciences, MycoPermeNet is a machine learning model trained on PAC-MAN screening data. The model identifies patterns in chemical structures to predict permeability.
How does machine learning predict molecular movement?
Small molecules are difficult to analyze through simple computation because they vary widely in size and molecular connections. A single measurement, such as weight, is insufficient to describe them.
According to Green, MycoPermeNet analyzes the chemical structure alone to predict how readily a compound permeates the mycomembrane. The model identifies specific physical properties and molecular substructures that allow a compound to bypass Mtb’s defenses. The research team found that these same features often correlate with a compound’s ability to kill the bacterium.
Who is involved in this research?
The study was published in the journal Nature Microbiology. The research was a collaborative effort between several institutions and was supported by the National Institutes of Health, the Gates Foundation, and the UMass Amherst Institute for Applied Life Sciences.
The research team included:
- Senior Authors: Sloan Siegrist (UMass Amherst), Anna Green (UMass Amherst), Marcos Pires (University of Virginia), Joel Freundlich (Rutgers University–New Jersey Medical School), and Wonpil Im (Lehigh University).
- Co-lead Authors: Irene Lepori (UMass Amherst), Nelson Evbarunegbe (UMass Amherst), Zichen Liu (University of Virginia), and Shasha Feng (Lehigh University).
Frequently Asked Questions
What is Mycobacterium tuberculosis (Mtb)?
Mtb is the bacterium that causes tuberculosis, a highly infectious disease that is difficult to treat due to its protective outer membrane.
What is the purpose of MycoPermeNet?
It is an AI-driven neural network designed to predict whether a chemical compound can penetrate the mycomembrane of Mtb based on its structure.
How does PAC-MAN differ from older methods?
Older methods required testing compounds individually, whereas PAC-MAN allows for parallel testing of multiple compounds simultaneously.
To stay updated on the latest breakthroughs in medical biotechnology and infectious disease research, subscribe to our newsletter or explore our related articles on AI in healthcare.
- Radio Bursts Reveal Universe’s Missing Matter
- Why the PlayStation Blackout Had Minimal Impact
- Breakthrough Salk Study Uncovers Mechanism Behind Immunotherapy Resistance: Interferons, Mitochondrial Dysfunction, and PGE2″ Interferons, mitochondrial dysfunction and PGE2: Salk study reveals mechanism behind immunotherapy resistance. Boost its search engine visibility with relevant keywords for maximum impact. Immunotherapy resistance remains one of the biggest hurdles in cancer treatment. According to a recent study published in the journal Nature Communications, scientists at the Salk Institute have made a groundbreaking discovery that sheds light on the underlying mechanisms behind this resistance. The study reveals that interferons, a type of protein that plays a crucial role in the immune system, can contribute to mitochondrial dysfunction in cancer cells. This dysfunction can lead to the production of prostaglandin E2 (PGE2), a molecule that promotes tumor growth and resistance to immunotherapy. In their study, the researchers found that PGE2 production was a key factor in the development of immunotherapy resistance in cancer cells. The team used a combination of experimental and computational models to investigate the relationship between interferons, mitochondrial dysfunction, and PGE2 production. The findings of the study suggest that targeting PGE2 production could be a potential strategy for overcoming immunotherapy resistance. The researchers propose that blocking PGE2 receptors or inhibiting its production could help restore the function of mitochondria in cancer cells, making them more susceptible to immunotherapy. The study’s authors hope that their findings will pave the way for the development of new therapies that can overcome immunotherapy resistance and improve treatment outcomes for cancer patients. Key Takeaways: – Interferons contribute to mitochondrial dysfunction in cancer cells – Mitochondrial dysfunction leads to PGE2 production, promoting tumor growth and resistance to immunotherapy – Targeting PGE2 production could be a potential strategy for overcoming immunotherapy resistance – Restoring mitochondrial function in cancer cells could make them more susceptible to immunotherapy Keywords: immunotherapy resistance, interferons, mitochondrial dysfunction, PGE2, Salk Institute, cancer treatment, breakthrough study, Nature Communications. (archyworldys.com)